BioReference Laboratories announced that it has acquired the Ariosa centralized laboratory prenatal testing business from Roche.
Ariosa’s non-invasive prenatal screening (NIPS) test, the Harmony Prenatal Test, has been performed in over 1.5 million patients. GenPath, BioReference’s specialty health division, currently offers ClariTest Core, which utilizes the same core technology as the Harmony Prenatal Test, so the acquisition of Ariosa will complement this current NIPS offering, BioReference Laboratories said.
